Recruiting

Observational Study

Sponsor:

National Human Genome Research Institute (NHGRI)

Code:

NCT00001456

Conditions

Hermansky-Pudlak Syndrome (HPS)

Eligibility Criteria

Sex: All

Age: 0 - 70+

Healthy Volunteers: Not accepted

Study Details

Brief summary:

Hermansky-Pudlak Syndrome (HPS) is an inherited disease which results in decreased pigmentation (oculocutaneous albinism), bleeding problems due to a platelet abnormality (platelet storage pool defect), and storage of an abnormal fat-protein compound (lysosomal accumulation of ceroid lipofuscin).

The disease can cause poor functioning of the lungs, intestine, kidneys, or heart. The major complication of the disease is pulmonary fibrosis and typically causes death in patients ages 40 - 50 years old. The disorder is common in Puerto Rico, where many of the clinical research studies on the disease have been conducted. Neither the full extent of the disease nor the basic cause of the disease is known. There is no known treatment for HPS.

The purpose of this study is to perform research into the medical complications of HPS and begin to understand what causes these complications. Researchers will clinically evaluate patients with HPS of all ethnic backgrounds. They will obtain cells, blood components (plasma), and urine for future studies. Genetic tests (mutation analysis) to detect HPS-causing genes will also be conducted.<TAB>

Conditions

Hermansky-Pudlak Syndrome (HPS)

Study ID

NCT00001456

Start date

Nov 6, 1995

Status verified date

Sep 4, 2026

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 0 - 70+

Healthy Volunteers: Not accepted

  • INCLUSION CRITERIA

Persons with HPS or family members who are their caregivers aged 1-80 years are eligible to enroll in this protocol. The diagnosis of HPS is based upon a paucity or deficiency of platelet dense bodies on whole mount electron microscopy or the identification of pathogenic variants in HPS genes by genetic testing. Some persons who have not been diagnosed with HPS may be admitted to the protocol based upon the presence of albinism and a platelet storage pool deficiency.

Subjects participating only in the HPS Symptom Questionnaire will be at least 18 years of age.

EXCLUSION CRITERIA

Pregnant women and adults who are unable to provide consent are excluded.

Study Design

Enrollment

600 participants

Anticipated

Interventions and Outcome Measures

Arms

HPS

HPS patients of any sex and ethnicity age 1-80 years

HPS Symptom Questionnaire

Includes both patients and family members or caregivers.

Primary outcome measure

  • Natural History [ Time Frame: Ongoing ]

Central Contacts and Locations

Central contacts

Wendy J Introne, M.D.

(301) 451-8879wi2p@nih.gov

Locations

National Institutes of Health Clinical Center

Recruiting

Bethesda, Maryland, United States, 20892

More Information

Sponsor

National Human Genome Research Institute (NHGRI)

Last update posted

Sep 9, 2026

Last verified

Sep 4, 2026

Keywords

  • Albinism
  • Platelet Storage Pool Deficiency
  • Metabolic Disease
  • Pulmonary Fibrosis
  • Inflammatory Bowel Disease
  • Natural History

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by National Human Genome Research Institute (NHGRI) on 2026-09-09.